Apomorphine infusion
( DrugBank: Apomorphine / KEGG DRUG: Apomorphine )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 15 |
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
Showing 1 to 10 of 15 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04887467 (ClinicalTrials.gov) | September 16, 202120210916 | 26/4/202120210426 | Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcu ... | Pharmacokinetic Study of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease Under Stabilized Treatment. Pharmacokinetic Study of Continuous and Diurnal Subcutaneous Apomorphine Infusionin Patients With Pa ... | Parkinson Disease | Drug: Apomorphine | Rennes University Hospital | NULL | Recruiting | 50 Years | 70 Years | Male | 20 | Phase 4 | France |
2 | EUCTR2021-000826-89-FR (EUCTR) | 23/04/202120210423 | 25/03/202120210325 | Etude pharmacocinétique de l’apomorphine en perfusion sous-cutanée continue diurne chez le patient parkinsonien équilibré sous traitement Etude pharmacocinétique de l’apomorphineen perfusion sous-cutanée continue diurne chez le patient pa ... | Etude pharmacocinétique de l’apomorphine en perfusion sous-cutanée continue diurne chez le patient parkinsonien équilibré sous traitement Etude pharmacocinétique de l’apomorphineen perfusion sous-cutanée continue diurne chez le patient pa ... | Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's di ... | Trade Name: APOKINON Product Name: APOKINON Product Code: N04BC07 | CHU Rennes | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 20 | Phase 4 | France | ||
3 | EUCTR2019-003315-60-NL (EUCTR) | 10/11/202020201110 | 08/10/202020201008 | A study investigating the effect and safety of a new potential drug for Parkinson's disease patients. A study investigating the effect and safety of a new potential drug for Parkinson's disease patients ... | A phase 1/2 study investigating the pharmacokinetics, safety and efficacy of a highly concentrated buccal formulation of apomorphine (APORON®) in subjects with Parkinson's Disease - Buccal apomorphine (APORON) administration A phase 1/2 study investigating the pharmacokinetics, safety and efficacy of a highly concentrated b ... | Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's di ... | Trade Name: Apo-go Product Name: APO-go® INN or Proposed INN: Apomorphine Other descriptive name: APOMORPHINE HYDROCHLORIDE HEMIHYDRATE Product Name: APORON INN or Proposed INN: APORON Other descriptive name: APOMORPHINE HYDROCHLORIDE HEMIHYDRATE Trade Name: Apo-go Product Name: APO-go® INN or Proposed INN: Apomorphine Other descriptive name: APOMO ... | Criceto IKM B.V. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 46 | Phase 1;Phase 2 | Netherlands | ||
4 | NCT02702076 (ClinicalTrials.gov) | May 201720170500 | 2/3/201620160302 | Apomorphine in Parkinson's Disease Patients With Visual Hallucinations | Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Continuous Subcutaneous Infusion in Parkinson's Disease Patients With Refractory Visual Hallucinations Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Continuous Subcutaneo ... | Parkinson's Disease;Hallucinations, Visual | Drug: Apomorphine;Drug: Placebo | University Medical Center Groningen | NULL | Recruiting | 30 Years | N/A | All | 35 | Phase 2 | Netherlands |
5 | EUCTR2016-000102-11-NL (EUCTR) | 23/11/201620161123 | 08/11/201620161108 | Trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with refractory visual hallucinations. Trial to evaluate the efficacy of continuous subcutaneous apomorphine infusionin Parkinson’s disease ... | Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with refractory visual hallucinations. - Apomorphine in PD patients with visual hallucinations: a RCT Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of continuous subcutaneo ... | Parkinson's disease patients with refractory visual hallucinations MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Parkinson's disease patients with refractory visual hallucinations MedDRA version: 19.0;Level: PT;Cl ... | Trade Name: APO-go Product Name: Apomorphine | University Medical Center Groningen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2;Phase 3 | Netherlands | |||
6 | EUCTR2016-002454-20-FR (EUCTR) | 17/10/201620161017 | 16/03/201720170316 | Apomorphine Pump in Early Stage of Parkinson’s Disease | Apomorphine Pump in Early Stage of Parkinson’s Disease - EARLY-PUMP | Parkinson’s disease MedDRA version: 19.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Parkinson’s disease MedDRA version: 19.1;Level: PT;Classification code 10061536;Term: Parkinson's di ... | Trade Name: APOKINON Product Name: APOKINON | CHU de Rennes | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 3 | France | |||
7 | EUCTR2014-000657-36-NL (EUCTR) | 22/06/201520150622 | 03/06/201520150603 | Trial to investigate the efficacy of treatments in apomorphine-induced skin reactions | Open-label crossover trial to investigate the efficacy of treatments in apomorphine-induced skin reactions - Treatment of apomorphine-induced skin reactions: a pilot study Open-label crossover trial to investigate the efficacy of treatments in apomorphine-induced skin rea ... | Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Hydrocortisone cream 10mg/g FNA Fagron Product Name: Hydrocortisone cream Trade Name: Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial' Product Name: Solu-Cortef Trade Name: APO-go Product Name: Apomorphine Trade Name: Hydrocortisone cream 10mg/g FNA Fagron Product Name: Hydrocortisone cream Trade Name: Solu ... | University Medical Center Groningen | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | Netherlands | ||
8 | NCT02339064 (ClinicalTrials.gov) | February 201520150200 | 31/3/201420140331 | Infusion of Apomorphine: Long-term Safety Study | A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of ApomorphineAdministered by C ... | Idiopathic Parkinson's Disease | Drug: apomorphine infusion | US WorldMeds LLC | NULL | Active, not recruiting | 30 Years | N/A | All | 99 | Phase 3 | United States |
9 | EUCTR2013-000980-10-DK (EUCTR) | 06/06/201420140606 | 09/01/201420140109 | Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s disease | TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson’s disease patients with motor complications not well controlled on medical treatment - TOLEDO TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the ... | Parkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment MedDRA version: 18.0;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Parkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment ... | Trade Name: Apo-go® Product Name: Apomorphine hydrochloride Product Code: Apo-go® INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: Apomorphine hydrochloride Trade Name: Apo-go® Product Name: Apomorphinehydrochloride Product Code: Apo-go® INN or Proposed INN: A ... | Britannia Pharmaceuticals Limited | NULL | Not Recruiting | Female: yes Male: yes | 102 | Phase 3 | France;Spain;Austria;Denmark;Netherlands;Germany | ||
10 | EUCTR2013-000980-10-FR (EUCTR) | 03/03/201420140303 | 22/11/201320131122 | Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s disease | TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson’s disease patients with motor complications not well controlled on medical treatment - TOLEDO TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the ... | Parkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment MedDRA version: 16.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Parkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment ... | Trade Name: Apo-go® Product Name: Apomorphine hydrochloride Product Code: Apo-go® INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: Apomorphine hydrochloride Trade Name: Apo-go® Product Name: Apomorphinehydrochloride Product Code: Apo-go® INN or Proposed INN: A ... | STADA Arzneimittel AG | NULL | Not Recruiting | Female: yes Male: yes | 102 | Phase 3 | France;Spain;Denmark;Austria;Netherlands;Germany |